Long-Term Outcomes of Ublituximab Treatment in Multiple Sclerosis: Findings from the ULTIMATE I and II Open-Label Extension Trials - Quiz - MDSpire

Long-Term Outcomes of Ublituximab Treatment in Multiple Sclerosis: Findings from the ULTIMATE I and II Open-Label Extension Trials

  • By

  • Bruce A. C. Cree

  • Edward Fox

  • Hans-Peter Hartung

  • Enrique Alvarez

  • Peiqing Qian

  • Sibyl Wray

  • Derrick Robertson

  • Krzysztof Selmaj

  • Daniel Wynn

  • Koby Mok

  • Chris Rowland

  • Karthik Bodhinathan

  • Peter Sportelli

  • Hari P. Miskin

  • Lawrence Steinman

  • April 1, 2026

  • 0 min

Share

Original Source(s)

Long-Term Outcomes of Ublituximab Treatment in Multiple Sclerosis: Findings from the ULTIMATE I and II Open-Label Extension Trials

  • by Bruce A. C. Cree, Edward Fox, Hans-Peter Hartung, Enrique Alvarez, Peiqing Qian, Sibyl Wray, Derrick Robertson, Krzysztof Selmaj, Daniel Wynn, Koby Mok, Chris Rowland, Karthik Bodhinathan, Peter Sportelli, Hari P. Miskin, Lawrence Steinman

  • April 1, 2026

Related Content

Bile acid metabolomics reveals distinct immunometabolic niches and enables accurate diagnosis of AQP4-IgG–seronegative NMOSD

Hippocampal neuronal hypoexcitability contributes to PTSD-like phenotypes in the experimental autoimmune encephalomyelitis model

Partial sensory rhizotomy in therapy-refractory and recurrent trigeminal neuralgia – a single center experience